NCT00395083

Brief Summary

EXECUTIVE SUMMARY: Purpose: To evaluate the efficacy and cost-effectiveness of a novel intervention incorporating self-management education, an action plan, and case-management to decrease the risk of hospitalizations due to chronic obstructive pulmonary disease (COPD) among veterans with severe COPD. Hypotheses: Primary Hypothesis: Veterans with COPD who receive a self-management program incorporating education sessions, development of an action plan, and case-management will have a decreased risk of COPD hospitalization compared to standardized COPD care. Primary Objective: In an intent-to-treat analysis, determine the efficacy of a comprehensive self-management program for reducing the risk of COPD hospitalization in veterans with severe COPD in comparison to patients receiving standardized COPD care. Secondary Hypotheses: Compared with standardized COPD care, veterans with COPD who receive a comprehensive self-management intervention will have: A) decreased health-related costs resulting from decreased hospitalizations and outpatient utilization, B) decreased hospitalization rates and average length of stay due to both COPD and all-cause admissions, and C) improvement in a set of outcomes including mortality, health-related quality of life, medication adherence, patient satisfaction, disease knowledge, skill acquisition and self-efficacy. Secondary Objectives: To evaluate the healthcare costs, hospitalization days, mortality, adherence, and health outcomes of a comprehensive self-management program compared to standardized COPD care among patients with severe COPD measured by: A)Healthcare-related costs B)Health services use due to COPD and to all causes C)Clinical outcome measures

  1. 1.Mortality
  2. 2.Health-related quality of life measured by generic and COPD-specific measures
  3. 3.Patient satisfaction
  4. 4.Medication adherence
  5. 5.Disease knowledge, skill acquisition and self-efficacy

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
426

participants targeted

Target at P75+ for phase_2

Timeline
Completed

Started Jul 2006

Typical duration for phase_2

Geographic Reach
1 country

22 active sites

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 1, 2006

Completed
4 months until next milestone

First Submitted

Initial submission to the registry

November 1, 2006

Completed
1 day until next milestone

First Posted

Study publicly available on registry

November 2, 2006

Completed
3.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2010

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2010

Completed
4 years until next milestone

Results Posted

Study results publicly available

August 21, 2014

Completed
Last Updated

September 15, 2014

Status Verified

September 1, 2014

Enrollment Period

4.2 years

First QC Date

November 1, 2006

Results QC Date

August 4, 2014

Last Update Submit

September 4, 2014

Conditions

Outcome Measures

Primary Outcomes (2)

  • Hospitalization-free Survival - Time to Event

    From randomization until date of first hospitalization for COPD, assessed up to 26 months

  • Hazard Ratio for First COPD Hospitalization

    26 months

Secondary Outcomes (2)

  • Hazard Ratio for All-Cause Mortality

    26 months

  • Time to All-Cause Death

    From randomization until death, assessed up to 26 months

Study Arms (2)

Group 1

NO INTERVENTION

Patients allocated to the control arm will receive standardized care that incorporates guide-line based recommendations including influenza vaccination, a short-acting bronchodilator, and either a long-acting bronchodilator or inhaled corticosteroid inhaler.

Group 2

EXPERIMENTAL

The comprehensive group will receive an initial, intense education program with development of an action plan, and regular telephone contacts by a case manager in addition to standardized COPD care.

Behavioral: COPD Self-management Education

Interventions

The comprehensive self-management intervention incorporates self-management education, development of an action plan, and case management. The intervention is designed using the social cognitive theory with the Precede-Proceed Model which has guided other successful patient education programs.

Group 2

Eligibility Criteria

Age40 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Population to be studied
  • The study population consists of VA patients with COPD who receive some of their medical care at Veterans Affairs medical centers and were hospitalized for COPD in the last 12 months. To ensure that patients enrolled in the study receive regular care at the participating VA, we will include only patients enrolled in either the primary care or pulmonary clinic at the VA medical center and were seen at least once in the last year. This criterion should not significantly decrease the number of eligible patients because 90% of patients admitted for COPD in the VA had at least 1 outpatient visit to the VA primary care clinic in the year prior to their hospitalization based on data from the VA OPC in FY03.
  • Diagnosis of COPD confirmed by all of the following:
  • FEV1/FVC \< 0.70
  • FEV1 \< 80%
  • Age \> 40 years
  • A current or past history of cigarette smoking (\> 10 pack-years)
  • COPD hospitalization in the previous year
  • Receives care at participating VA medical center
  • Enrolled in either primary care or pulmonary clinic at the VA
  • Seen at least once in the past year in either primary care or pulmonary clinic
  • No COPD exacerbations in last 4 weeks
  • English-speaking
  • Access to telephone

You may not qualify if:

  • Primary clinical diagnosis of asthma
  • Medical conditions affecting the ability to participate in the study such as:
  • Comorbid illness likely to limit life expectancy \< 1 year
  • Decompensated heart failure
  • Dementia
  • Uncontrolled psychiatric illness
  • Participation in another clinical intervention trial in the previous 30 days

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (22)

Carl T. Hayden VA Medical Center

Phoenix, Arizona, 85012, United States

Location

Southern Arizona VA Health Care System, Tucson

Tucson, Arizona, 85723, United States

Location

VA Medical Center, Loma Linda

Loma Linda, California, 92357, United States

Location

VA Palo Alto Health Care System

Palo Alto, California, 94304-1290, United States

Location

VA Medical Center, Bay Pines

Bay Pines, Florida, 33708, United States

Location

North Florida/South Georgia Veterans Health System

Gainesville, Florida, 32608, United States

Location

Atlanta VA Medical and Rehab Center, Decatur

Decatur, Georgia, 30033, United States

Location

Richard Roudebush VA Medical Center, Indianapolis

Indianapolis, Indiana, 46202-2884, United States

Location

Robert J. Dole VAMC & ROC, Wichita

Wichita, Kansas, 67218, United States

Location

VA Medical Center, Lexington

Lexington, Kentucky, 40502, United States

Location

VA Medical Center, Kansas City MO

Kansas City, Missouri, 64128, United States

Location

New Mexico VA Health Care System, Albuquerque

Albuquerque, New Mexico, 87108-5153, United States

Location

VA Western New York Healthcare System at Buffalo

Buffalo, New York, 14215, United States

Location

New York Harbor HCS

New York, New York, 10010, United States

Location

VA Medical Center, Cincinnati

Cincinnati, Ohio, 45220, United States

Location

VA Medical Center, Oklahoma City

Oklahoma City, Oklahoma, 73104, United States

Location

VA Medical Center, Providence

Providence, Rhode Island, 02908, United States

Location

VA North Texas Health Care System, Dallas

Dallas, Texas, 75216, United States

Location

Michael E. DeBakey VA Medical Center (152)

Houston, Texas, 77030, United States

Location

VA South Texas Health Care System, San Antonio

San Antonio, Texas, 78229, United States

Location

Hunter Holmes McGuire VA Medical Center

Richmond, Virginia, 23249, United States

Location

VA Puget Sound Health Care System

Seattle, Washington, 98101, United States

Location

Related Publications (1)

  • Fan VS, Gaziano JM, Lew R, Bourbeau J, Adams SG, Leatherman S, Thwin SS, Huang GD, Robbins R, Sriram PS, Sharafkhaneh A, Mador MJ, Sarosi G, Panos RJ, Rastogi P, Wagner TH, Mazzuca SA, Shannon C, Colling C, Liang MH, Stoller JK, Fiore L, Niewoehner DE. A comprehensive care management program to prevent chronic obstructive pulmonary disease hospitalizations: a randomized, controlled trial. Ann Intern Med. 2012 May 15;156(10):673-83. doi: 10.7326/0003-4819-156-10-201205150-00003.

MeSH Terms

Conditions

Pulmonary Disease, Chronic ObstructiveEmphysema

Condition Hierarchy (Ancestors)

Lung Diseases, ObstructiveLung DiseasesRespiratory Tract DiseasesChronic DiseaseDisease AttributesPathologic ProcessesPathological Conditions, Signs and Symptoms

Results Point of Contact

Title
Dr. Sarah Leatherman
Organization
VA Boston Healthcare System - MAVERIC

Study Officials

  • Vincent S. Fan, MD MPH

    VA Puget Sound Health Care System

    STUDY CHAIR

Publication Agreements

PI is Sponsor Employee
Yes

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
NONE
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
FED
Responsible Party
SPONSOR

Study Record Dates

First Submitted

November 1, 2006

First Posted

November 2, 2006

Study Start

July 1, 2006

Primary Completion

September 1, 2010

Study Completion

September 1, 2010

Last Updated

September 15, 2014

Results First Posted

August 21, 2014

Record last verified: 2014-09

Locations